We either (i) added the pan DNMT inhibitor 5-aza-2’-deoxycytidine (DM + SGLT2i + aPC+aza; 5-aza-2’-deoxycytidine reduces DNMT1 activity and its expression27) or (ii) specifically inhibited DNMT1 expression (using vivo-morpholino28, DM + SGLT2i + aPC+DNMTi) on top of SGLT2i and aPC treatment in mice with 16 weeks of established hyperglycemia (Fig. 7a). Here, DNMT1 is linked to Hyperglycemia.